StockData
Immunic, Inc. logo

Immunic, Inc. (IMUX) stock

IMUXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$7.33+0.10 (+1.38%)

Close on Nov 17, 2026Market cap $100.01MP/E –Yield 0.00%

Immunic cash

Cash and short-term investments held at the end of each period.

Immunic's cash was $155.10M at Jun 30, 2026. For fiscal 2025 it was $15.48M, down 56.6% from the year before. Over ten years it grew -15.5% a year on average. The highest annual figure on record is $127.45M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$15.48M-56.6%
FY2024Dec 31, 2024$35.67M-23.6%
FY2023Dec 31, 2023$46.67M-56.3%
FY2022Dec 31, 2022$106.75M+22.9%
FY2021Dec 31, 2021$86.86M-31.8%
FY2020Dec 31, 2020$127.45M+334.0%
FY2019Dec 31, 2019$29.37M+124.7%
FY2018Dec 31, 2018$13.07M+190.2%
FY2017Dec 31, 2017$4.50M-92.5%
FY2016Dec 31, 2016$59.99M-28.1%
FY2015Dec 31, 2015$83.42M-18.4%
FY2014Dec 31, 2014$102.24M+167.7%
FY2013Dec 31, 2013$38.19M+752.9%
FY2012Dec 31, 2012$4.48M+457.5%
FY2011Dec 31, 2011$803.00K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$155.10M+180.4%
Q1 FY2026Mar 31, 2026$186.63M+1204.7%
Q4 FY2025Dec 31, 2025$15.48M-56.6%
Q3 FY2025Sep 30, 2025$35.13M-40.5%
Q2 FY2025Jun 30, 2025$55.31M-30.6%
Q1 FY2025Mar 31, 2025$14.30M-85.3%
Q4 FY2024Dec 31, 2024$35.67M-23.6%
Q3 FY2024Sep 30, 2024$59.07M-1.0%
Q2 FY2024Jun 30, 2024$79.70M+3.1%
Q1 FY2024Mar 31, 2024$97.31M+4.9%
Q4 FY2023Dec 31, 2023$46.67M-56.3%
Q3 FY2023Sep 30, 2023$59.69M-18.0%
Q2 FY2023Jun 30, 2023$77.29M-12.2%
Q1 FY2023Mar 31, 2023$92.76M-3.1%
Q4 FY2022Dec 31, 2022$106.75M+22.9%
Q3 FY2022Sep 30, 2022$72.77M-34.1%
Q2 FY2022Jun 30, 2022$88.08M+1.0%
Q1 FY2022Mar 31, 2022$95.71M-16.7%
Q4 FY2021Dec 31, 2021$86.86M-31.8%
Q3 FY2021Sep 30, 2021$110.44M-17.1%
Q2 FY2021Jun 30, 2021$87.18M+79.3%
Q1 FY2021Mar 31, 2021$114.84M+518.1%
Q4 FY2020Dec 31, 2020$127.45M+334.0%
Q3 FY2020Sep 30, 2020$133.18M+337.2%
Q2 FY2020Jun 30, 2020$48.61M+34.6%
Q1 FY2020Mar 31, 2020$18.58M+144.7%
Q4 FY2019Dec 31, 2019$29.37M+124.7%
Q3 FY2019Sep 30, 2019$30.46M+204.0%
Q2 FY2019Jun 30, 2019$36.12M+197.8%
Q1 FY2019Mar 31, 2019$7.59M-82.6%
Q4 FY2018Dec 31, 2018$13.07M+190.2%
Q3 FY2018Sep 30, 2018$10.02M-84.9%
Q2 FY2018Jun 30, 2018$12.13M-84.1%
Q1 FY2018Mar 31, 2018$43.65M-49.6%
Q4 FY2017Dec 31, 2017$4.50M-92.5%
Q3 FY2017Sep 30, 2017$66.39M-2.5%
Q2 FY2017Jun 30, 2017$76.15M–
Q1 FY2017Mar 31, 2017$86.64M–
Q4 FY2016Dec 31, 2016$59.99M–
Q3 FY2016Sep 30, 2016$68.09M–

More Immunic figures

See a number that looks wrong?